Advanced Breast Cancer
Olema Pharmaceuticals Inc. focuses on ER+, HER2- advanced breast cancer, including metastatic breast cancer and disease after endocrine therapy and CDK 4/6 inhibitor treatment. Its clinical research is centered on hormone receptor-driven disease and treatment settings where resistance to standard endocrine approaches is a major concern.
- ER+/HER2- advanced breast cancer
- Metastatic breast cancer
- Endocrine-resistant disease
- CDK 4/6 inhibitor combination treatment
The sponsor’s studies include both monotherapy and combination strategies aimed at improving disease control in advanced breast cancer populations.
Hormone Receptor–Targeted Oncology
The company’s research landscape is strongly aligned with hormone receptor-positive cancers, especially tumors driven by estrogen receptor signaling. This includes investigation of agents designed for use alongside established endocrine backbones such as letrozole and ribociclib.
- Estrogen receptor-positive tumors
- Endocrine-based treatment regimens
- First-line advanced breast cancer
- Combination endocrine therapy
Its trial portfolio reflects a therapeutic interest in refining treatment options for ER+ disease across advanced and metastatic settings.
Solid Tumor Oncology
Beyond breast cancer, Olema Pharmaceuticals supports research in advanced or metastatic solid tumors, indicating broader interest in oncology programs that address difficult-to-treat solid malignancies. This area extends the sponsor’s therapeutic scope into heterogeneous tumor types with unmet clinical need.
- Advanced solid tumors
- Metastatic malignancies
- Oncology drug development
These studies position the sponsor within the broader field of solid tumor therapeutics while maintaining a clear emphasis on advanced disease.
Clinical Development in Breast and Solid Tumor Therapy
The sponsor’s funded trials span multiple active research sites across several countries, supporting evaluation of new treatment approaches in breast cancer and solid tumor oncology. The clinical focus remains on therapies intended for patients with advanced disease who have limited options after prior treatment exposure.
- Multinational oncology research
- Advanced disease treatment
- Therapies for previously treated cancer
The research portfolio is concentrated on therapeutic areas where improved disease control and expanded options are needed in oncology.
